Abstract:The objectives of the present study were to investigate the effect of ANG-(1-7) on the development of cardiac hypertrophy and to identify the intracellular mechanism underlying this action of ANG-(1-7). Blood pressure and heart rate were recorded using radiotelemetry before and after chronic subcutaneous infusion of control (PBS), ANG II, ANG-(1-7), or ANG II + ANG-(1-7) for 4 wk in normotensive rats. Chronic administration of ANG-(1-7) did not affect either basal blood pressure or the ANG II-induced elevation in blood pressure. However, ANG-(1-7) significantly attenuated ANG II-induced cardiac hypertrophy and perivascular fibrosis in these rats. These effects of ANG-(1-7) were confirmed in cultured cardiomyocytes, in which ANG-(1-7) significantly attenuated ANG II-induced increases in cell size. This protective effect of ANG-(1-7) was significantly attenuated by pretreatment with A779 (a Mas receptor antagonist) or Mito-TEMPO (a mitochondria-targeting superoxide scavenger) as well as blockade of Sirt3 (a deacetylation-acting protein) by viral vector-mediated overexpression of sirtuin (Sirt)3 short hairpin (sh)RNA. Western blot analysis demonstrated that treatment with ANG-(1-7) dramatically increased Sirt3 expression. In addition, ANG-(1-7) attenuated the ANG II-induced increase in mitochondrial ROS generation, an effect that was abolished by A779 or Sirt3 shRNA. Moreover, ANG-(1-7) increased FoxO3a deacetylation and SOD2 expression, and these effects were blocked by Sirt3 shRNA. In summary, the protective effects of ANG-(1-7) on ANG II-induced cardiac hypertrophy and increased mitochondrial ROS production are mediated by elevated SOD2 expression via stimulation of Sirt3-dependent deacetylation of FoxO3a in cardiomyocytes. Thus, activation of the ANG-(1-7)/Sirt3 signaling pathway could be a novel therapeutic strategy in the management of cardiac hypertrophy and associated complications.NEW & NOTEWORTHY Chronic subcutaneous ANG-(1-7) has no effect on ANG II-induced elevations in blood pressure but significantly attenuates ANG II-induced cardiac hypertrophy and fibrosis by a mitochondrial ROS-dependent mechanism. This protective effect of ANG-(1-7) against the action of ANG II action is mediated by stimulation of sirtuin-3-mediated deacetylation of FoxO3a, which triggers SOD2 expression.

Osteocrin Alleviates Cardiac Hypertrophy Via Attenuating Oxidative Stress.

Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity

Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity

A New Secretory Peptide of Natriuretic Peptide Family, Osteocrin, Suppresses the Progression of Congestive Heart Failure After Myocardial Infarction

OS 36-06 OSTEOGLYCIN INHIBITS HYPERTENSIVE CARDIAC FIBROSIS THOUGH SUPPRESSION OF EGFR SIGNALING

599 APOCYNIN AND EPLERENONE ATTENUATES OXIDATIVE STRESS AND CARDIAC FIBROSIS IN ANGIOTENSIN II-INDUCED CARDIAC DIASTOLIC DYSFUNCTION

Apocynin Attenuates Oxidative Stress and Cardiac Fibrosis in Angiotensin II-induced Cardiac Diastolic Dysfunction in Mice

Osthole Regulates TGF-β1 and MMP-2/9 Expressions Via Activation of PPARα/γ in Cultured Mouse Cardiac Fibroblasts Stimulated with Angiotensin II.

Role of Osteopontin in Cardiac Fibrosis and Remodeling in Angiotensin Ii - Induced Cardiac Hypertrophy

Reduction of Rat Cardiac Hypertrophy by Osthol is Related to Regulation of Cardiac Oxidative Stress and Lipid Metabolism

Cardiac Oxidative Signaling and Physiological Hypertrophy in the Na/K-ATPase α1s/sα2s/s Mouse Model of High Affinity for Cardiotonic Steroids

Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling

Sustained Oligomycin Sensitivity Conferring Protein Expression in Cardiomyocytes Protects Against Cardiac Hypertrophy Induced by Pressure Overload Via Improving Mitochondrial Function

Nobiletin, a Polymethoxy Flavonoid, Protects Against Cardiac Hypertrophy Induced by Pressure-Overload via Inhibition of NAPDH Oxidases and Endoplasmic Reticulum Stress.

Abstract 17040: Selective Inhibition of Myocardial NADPH Oxidase with a Dominant-Negative Mutant of P67 Phox Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Adult Transgenic Mice

Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism

Osteoglycin Attenuates Cardiac Fibrosis by Suppressing Cardiac myofibroblast proliferation and migration throughAntagonizing LPA3/MMP2/EGFR signaling.

A1304 Osteoglycin Attenuates Cardiac Fibrosis by Suppressing Cardiac myofibroblast proliferation and migration throughAntagonizing LPA3/MMP2/EGFR signalling

Human paraoxonase gene cluster overexpression alleviates angiotensin II-induced cardiac hypertrophy in mice

Ang II Promotes Cardiac Autophagy and Hypertrophy via Orai1/STIM1

Angiotensin-(1-7) Attenuates Angiotensin II-induced Cardiac Hypertrophy Via a Sirt3-dependent Mechanism.